Alveolar and postcranial bone density in postmenopausal @entity1 receiving hormone/ XXXX replacement therapy: a randomized, double-blind, placebo-controlled trial.

@entity172 @entity1 @entity9646 @entity11796 @entity2520 @entity17916 @entity3875 @entity4067 @entity4959
BACKGROUND: We conducted a 3-year, double-blind, randomized, placebo-controlled study to determine whether the positive effects of hormone/ @entity172 replacement therapy (H/ERT) on postcranial bone density are accompanied by similar positive effects on oral bone mass. METHODS: A total of 135 postmenopausal @entity1 (aged 41-70 years) with no evidence of moderate or severe @entity2520 were randomized to receive daily oral conjugated @entity172 ( @entity17916 ; 0.625 mg) alone or in combination with @entity11796 (Prempro; 0.625 and 2.5 mg, respectively) or placebo. All subjects received @entity4959 (1000 mg/d) and @entity3875 (400 [corrected] IU/d) supplements. The primary efficacy end points were the changes in @entity4067 height and alveolar bone density. @entity4067 height was measured on bite-wing radiographs, and changes in alveolar bone mass were assessed by means of digital-subtraction radiography. Postcranial bone density was measured in the lumbar spine and left proximal femur by means of dual-energy x-ray absorptiometry. RESULTS: @entity9646 / @entity172 replacement therapy significantly increased alveolar bone mass compared with placebo (+1.84% vs +0.95% [P =.04]), and tended to improve @entity4067 height (+4.83% vs +3.46% [P =.34]). Bone mineral density of the proximal femur significantly increased in the H/ERT compared with the placebo group (total proximal femur, +3.59% vs +0.22% [P =.001]; neck, +2.05% vs -0.34% [P =.02]; trochanter, +3.49% vs +0.08% [P<.001]), but not the lumbar spine (+1.01% vs +0.17% [P =.39]). Changes in alveolar bone mass correlated with bone density changes in the total femur (r = 0.28 [P =.02]) and femoral trochanter (r = 0.25 [P =.04]) in the H/ERT but not in the placebo group. CONCLUSIONS: Postcranial and oral bone mass were increased in postmenopausal @entity1 receiving H/ERT. Improvement in oral bone health constitutes an additional benefit of H/ERT.
